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Background:  Clonidine, an α-2 adrenergic agonist, is used in the perioperative period and in intensive care for 
the management of hypertension.  The in vivo and in vitro effects of clonidine on the actions of nondepolarizing 
neuromuscular blocking drugs are conflicting.  We evaluated the potency and time course of rocuronium-induced 
neuromuscular block after prolonged pretreatment with clonidine in rabbits.
Methods:  Sixty rabbits were randomly assigned to three groups; control (C) group: normal saline 0.1 ml/kg daily 
subcutaneous for 6 weeks; S3 group: clonidine 4 μg/kg daily subcutaneous for 3 weeks; S6 group: clonidine 4 μg/kg 
daily subcutaneous for 6 weeks.  The dose-response relations of rocuronium were tested in 30 rabbits (10 from each 
of the three groups) during ketamine-thiopental anesthesia, while the time course of rocuronium 0.6 mg/kg was 
examined in 10 rabbits each from the three groups.
Results:  There was no difference in mean arterial pressure and pulse rate among the experimental groups.  The 
calculated ED50 for rocuronium decreased significantly from 64.1 μg/kg (C group) to 50.3 μg/kg (S3 group) and 47.8 
μg/kg (S6 group) (P < 0.001).  There was no difference in the onset and the recovery times after rocuronium.
Conclusions:  Rocuronium after pretreatment with clonidine for three or six weeks may have an increased effect, but 
no difference in the duration of action compared with control group.  (Korean J Anesthesiol 2010; 59: 190-195)
Key Words:  Clonidine, Pharmacodynamics, Rabbits, Rocuronium.
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Introduction
    Clonidine (Catapres
Ⓡ, Boehringer Ingelheim Pharmaceuticals, 
Inc. U.S.A.), an α-2 adrenergic agonist, has been used in 
management of hypertension for more than 35 years and is 
administered as a long-term infusion during surgery to prevent 
myocardial ischemia [1]. Due to its sedative and analgesic 
effects, preoperative administration of clonidine reduces opioid 
or anesthetic requirements and anxiety [2], to stabilize excessive 
changes in blood pressure and pulse rate resulting from pain 
from tracheal intubation and surgery by inhibiting sympathetic 
reactions, and also to increase skin temperature [3]. The 
interaction of clonidine and nondepolarizing muscle relaxants is 
unclear: oral clonidine enhances vecuronium-induced muscle 
relaxation in one study [4], but not in others [5]. Clonidine does 
not increase acetylcholine release from the neuromuscular 
junction and does not enhance neuromuscular contraction in 
vitro [6]. In nerve-hemidiaphragm models, clonidine does not 
influence d-tubocurarine-induced spasmolysis [7], while high 
concentrations of clonidine enhance rocuronium-induced 
muscle relaxation [8]. Consequently, we have conflicting results 
from both in vivo and in vitro experiments on the effects of 
clonidine [4-8].
    Rocuronium bromide (rocuronium) (Esmeron
Ⓡ, Korean 
Organon Inc., Seoul, Korea) is a steroidal nondepolarizing 
muscle relaxant frequently used in modern anesthesia, with a 
more rapid onset than conventional nondepolarizing muscle 
relaxants and an intermediate duration of action similar to 
vecuronium [9]. 
    To date, all interactions between clonidine and muscle 
relaxants have been based on results of preoperative admini-
stration of clonidine for a few hours, whereas clinical practices 
require longer administration. We used rabbits to test whether 
long-term administration of clonidine would affect rocuronium-
induced muscle relaxation.
Materials and Methods
    The study was approved by the Animal Care and Use Com-
mittee of our hospital. Adult male rabbits (weighing 2-3 kg, n 
= 60) were randomly assigned to three groups (20 each). The 
control (C) group received one subcutaneous injection of 0.1 
ml/kg normal saline daily for 6 weeks on the opposite hip of the 
experimental region. The S3 group received 4 μg/kg clonidine 
daily subcutaneously for 3 weeks. The S6 group received 4 
μg/kg clonidine daily subcutaneously for 6 weeks. Clonidine 
doses were determined by weighing rabbits before each 
administration.
    For pre-treatment, anesthesia was induced by a subcutaneous 
injection of 10-15 mg/kg ketamine (Ketara
Ⓡ, Yuhan Corp., 
Seoul, Korea) and the intravenous route was secured by a 22-G 
catheter, through which 0.9% of saline solution was provided 
at 6 ml/kg/h using an infusion pump (STC 523, Terumo Co., 
Tokyo, Japan). After intravenous injection of 5 mg/kg thiopental 
sodium (Pentotalsodium
Ⓡ, Choongwae Pharma Corp., Korea), 
tracheotomy was performed and an endotracheal tube (ID = 
2.5-3.0 mm) was inserted and attached to an animal ventilator 
(SN-480-5, Shinano Co., Tokyo, Japan). Controlled respiration 
was performed with PETCO2 at 30-35 mmHg using an ETCO2/
SpO2 monitor (CO2SMO
Ⓡ, Novametrix Co., Wallingford, CT, 
USA), while tidal volume (TV) was set at 25 ml/kg; tidal rate (TR), 
30-35 breath/min; inspiration time : expiration time (I : E) ratio 
= 1 : 2. Arterial blood gas analysis (ABGA) was intermittently 
performed using GEM-STAT
Ⓡ gas analyzer (Mallinckrodt 
Co., Ann Arbor, MI, USA). For continuous management of 
anesthesia, thiopental sodium was infused by an infusion pump 
at the rate of 26 mg/kg/h. 
    Rectal temperature was kept at 38
oC using a thermostat 
(Blanketrol II, 222, Cincinnati Sub-Zero Co., Cincinnati, OH, 
USA) and a heat lamp. After catheterization of a 22-G catheter 
into the right common carotid artery, a monitoring system 
(SpaceLabs
Ⓡ, 90603A
Ⓡ, SpaceLabs Co., Redmond, WA, USA) 
was established to measure arterial pressure and ECG. At 20 
minutes after all manipulations were completed, which was 
required for stabilizing the animals, the mean arterial pressure 
and pulse were measured 10 minutes before and after each 
administration of muscle relaxants.
    To sample neuromuscular specimens, the anterior tibial 
muscle was removed and exposed and its distal part was 
dissected, cut off, and the isolated strip was suspended at the 
tendon from a force displacement transducer (45196A
Ⓡ, San-
ei Co., Tokyo, Japan) using a 3-0 silk suture connected to a 
physiologic recording device (Biophysiograph 7748
Ⓡ, San-ei Co, 
Japan) for continuous recording of myospasm. After the same-
sided femoral region and the distal part of the anterior tibia 
were fixed, resting tension was maintained at the anterior tibial 
muscle with a preload of 20 g. 
    The common peroneal nerve was exposed out of the left 
upper knee joint, dissected, and positioned on wire bipolar 
electrodes. The twitch response at the anterior tibial muscle 
was elicited by a train-of-four (TOF) supramaximal square-
wave stimuli for 0.2 milliseconds (ms) every 10 second (s) 
using a peripheral nerve stimulator (DualStim
Ⓡ, Life-Tech Inc., 
Houston, TX, USA), and the lengths/intervals of the first twitch 
(T1) from TOF stimulation were compared.
Experiment I
    Thirty rabbits were divided into three groups with 10 rabbits 
each. To maintain animal stability, the lengths/intervals of 192 www.ekja.org
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control twitch were measured with continuous TOF stimulation 
at 10 s intervals 20 min after all manipulations were completed. 
For Group S3 and S6, an intravenous dose of rocuronium 40, 60, 
and 80 μg/kg was injected, with 40, 80 and 120 μg/kg infused 
in Group C. Neuromuscular block was quantified by the first 
twitch (T1) of the TOF. To obtain dose-response curves, the 
suppression ratio of T1 was expressed in probit coordinates, 
the amount in logarithm coordinates, while rocuronium, 
having an intermediate duration of action, was tested using 
the single-dose method [9] using doses determined during 
a pilot study. The comparison of the dose-response curves 
was made using analysis of covariance (ANCOVA), and the 
effective doses (ED50, ED95) at the time of 50% and 95% of 
twitch suppression were calculated. All muscle relaxants were 
intravenously injected within <5 s. The next dose of medication 
was provided after at least 2-fold longer wait than the duration 
of action of the previous administration following full recovery. 
After completion of the experiment, the rabbits were given a 
lethal dose of thiopental sodium and potassium chloride by 
intravenous injection. 
Experiment II
    We used 30 rabbits (10 from each group) in this experiment. 
For each group, 0.6 mg/kg rocuronium was intravenously 
infused and the inhibition and recovery of twitch were recorded 
and observed during spontaneous recovery. The twitch 
recordings were evaluated for the following variables: time from 
end of injection of rocuronium to maximal twitch suppression 
(onset); time from end of injection of the initial dose to recovery 
of T1 in the TOF to the recurrence and a value of 25%, 75%, 
and 95% of control twitch tension (T1[1, 25, 75, 95]); time from 
25% to 75% twitch recovery (recovery index; RI); time from end 
of injection of the initial dose to a TOF ratio (T4/T1) of 70% 
(TOF(70)). At the end of the experiments, animals were given 
a lethal dose of thiopental sodium and potassium chloride by 
intravenous injection. 
Statistics
    Statistical analyses were performed using SPSS (version 17.0, 
SPSS Inc, Chicago, USA), and statistical evaluations of slope at 
ED50 and ED95 were confirmed by linear regression analysis and 
analysis of covariance (ANCOVA). Pharmocodynamic effects 
were confirmed by one way analysis of variance (ANOVA), 
whereas differences between the groups were evaluated by 
Bonferroni multiple range t-test. All data are expressed as mean 
± SD, and P < 0.05 was accepted as statistically significant. 
Results
    The mean arterial blood pressures of Group C, S3, and S6 
were 77.4 ± 11.3 mmHg, 70.4 ± 10.5 mmHg, and 71.5 ± 10.8 
mmHg, respectively; S3 and S6 were lower than group C. Pulse 
rates were similar in all groups, although Groups S3 and S6 were 
lower than Group C: Group C, 280.4 ± 19.3 beats/min; Group 
S3, 268.9 ± 16.6 beats/min; Group S6, 271.4 ± 17.8 beats/min. 
    The ED50 of rocuronium was 64.1 ± 7.8 μg/kg for Group C, 50.3 
± 6.7 μg/kg for Group S3, and 47.8 ± 6.5 μg/kg for S6. The ED95 of 
rocuronium were 98.3 ± 12.5 μg/kg, 75.8 ± 9.7 μg/kg, and 66.5 ± 
8.6 μg/kg, respectively, with significant decreases in Group S3 
and S6 versus Group C (P < 0.001)(Table 1). The dose-response 
curve was shifted significantly leftward in Group S3 and S6 (P < 
0.001) compared with Group C, but the slopes were similar: 4.7 
± 1.1, 4.3 ± 0.9, and 5.4 ± 1.4, respectively (Table 1, Fig. 1).
    The onset times for Group C, S3 and S6 were 0.4 ± 0.2 min, 
0.4 ± 0.1 min, and 0.3 ± 0.1 min, respectively. The time from 
the end of rocuronium injection until the reappearance of T1 
was similar: 13.5 ± 1.7 min, 14.2 ± 1.7 min, and 15.1 ± 1.9 min, 
Fig. 1. Dose-response curves of rocuronium obtained by log 
dose-probit linear regression for twitch depression after chronic 
pretreatment with clonidine in rabbits. Individual points represent 
mean (95% confidence intervals) twitch depression (% control) with 
each dose. *P < 0.001 compared with control values.
Table 1. Dose-Response Data of Rocuronium in Rabbits after 
Clonidine 4 μg/kg Daily Subcutaneous Injection for 3 or 6 Weeks
Group C
(n = 10)
Group S3
(n = 10)
Group S6
(n = 10)
ED25 (µg/kg)
ED50 (µg/kg)
ED95 (µg/kg)
Slope (probit/log)
52.5 ± 5.1
64.1 ± 7.8
98.3 ± 12.5
4.7 ± 1.1
39.7 ± 4.7*
50.3 ± 6.7*
75.8 ± 9.7*
4.3 ± 0.9
39.4 ± 4.5*
47.8 ± 6.5*
66.5 ± 8.6*
5.4 ± 1.4
Data are expressed as mean ± SD. Group C: control group, Group S3: 
after Clonidine 4 μg/kg daily sq for 3 weeks, Group S6: after Clonidine 
4 μg/kg daily sq for 6 weeks. ED50: 50% effective dose, ED95: 95% 
effective dose, *P < 0.001 compared with the control group.193 www.ekja.org
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respectively (Table 2). The times of 95% recovery of T1 were 22.6 
± 3.1 min, 22.8 ± 2.9 min, and 21.3 ± 2.8 min, and the recovery 
times of the TOF ratio to 70% were 24.1 ± 3.4 min, 24.5 ± 3.1 min, 
and 23.9 ± 2.9 min, respectively, for Group C, S3, and S6 (Table 
2). No differences were noted in the recovery index (25-75%) 
of Group C, S3, and S6: 3.8 ± 0.7 min, 4.3 ± 0.8 min, and 3.8 ± 0.7 
min, respectively.
Discussion
    Clonidine, 4 μg/kg daily subcutaneous injection, for 3 or 
6 weeks significantly left-shifted the dose-response curve of 
rocuronium but did not change the onset and recovery times 
after intravenous injection of rocuronium (0.6 mg/kg), although 
mean arterial pressure and pulse rate tended to decline. 
    Clonidine is a direct-acting α-2 adrenergic receptor agonist 
(an imidazole derivative) with more affinity for α-2 than α-1 
adrenergic receptors, acting on sympathetic preganglionic 
neurons to suppress the effects of norepinephrine or 
phenylephrine on α-1 vasoconstriction and allows blood 
vessels to relax [10]. Intravenous administration of clonidine 
(5 μg/kg) 10 min before anesthetic induction in human adults 
reduced endotracheal intubation-induced increases in blood 
pressure (BP) and pulse rates [11], while a pre-anesthetic 
injection of clonidine (0.2 mg) into muscle reduced systolic 
BP caused by strong stimuli such as endotracheal intubation, 
but had no effects on diastolic BP and pulse rates [12]. In 
laparoscopic cholecystectomy, intravenous administration 
of 0.15 mg clonidine for 10 min after the start of operation 
suppresses increases in BP and pulse rates during surgery 
[13]. Long-term administration of clonidine in patients with 
serious hypertension also slightly reduced BP and pulse rates, 
but did not influence cardiac output, blood flow rate, renal 
plasma flow, and glomerular filtration rate (GFR) [14]. Long-
term administration of clonidine in rats reduced BP and pulse 
rate for the first two days, but thereafter did not change BP 
and pulse [15], perhaps due to clonidine tolerance [16]. Here 
clonidine showed a tendency to reduce BP and pulse rates. The 
clinical dose of 4 μg/kg/day is not excessive but leads to central 
sympathetic block by long-term stimulation of α-2 adrenergic 
receptors that is offset by peripheral vasoconstriction [17]. 
The similarities in 3-week and 6-week treatments probably 
resulted from a decrease in the threshold and sensitivity of the 
arterial baroreceptor reflex due to long-term administration of 
clonidine [18].
    In a human trial, oral administration of clonidine 4-5.5 μg/
kg 90 min before anesthetic induction increased the duration 
of muscle relaxation produced by 0.1 mg/kg vecuronium by of 
26.4% [4]. However, the study used isoflurane as an inhalation 
anesthetic on only 8 subjects; the small sample size and 
interactions with inhalation anesthetics should be considered. A 
different study of oral clonidine 5 μg/kg 90 min before anesthetic 
induction in humans did not influence the duration of muscle 
relaxation produced by 0.1 mg/kg vecuronium in 21 subjects 
and not using inhalation anesthetics [5]. We also did not find 
clonidine-induced alterations in the duration of neuromuscular 
blockade. In a study using a nerve-hemidiaphragm model, 
clonidine 50 μM induced leftward shifts in rocuronium dose-
response curves [8]. We also found dose-response curves for 
rocuronium that shifted leftward, indicating enhancement 
of rocuronium-induced muscle relaxation, in contrast to 
previous results that clonidine does not affect muscle relaxants 
[7]. Clonidine, which suppresses both plasma catecholamine 
and acetylcholine [19], induces leftward shifts of rocuronium 
dose-response curves as in the present study. Because shifts 
in the rocuronium dose-response curves were not blocked by 
yohimbine (α-2 adrenergic receptor blocker) and a small dose 
of clonidine did not shift the dose-response curves, rocuronium 
curve shifts are not induced by α-2 adrenergic receptors 
[8]. Catecholamine (norepinephrine and epinephrine) given 
intra-arterially or intravenously administered to stimulate α-1 
adrenergic receptors, enhanced the release of acetylcholine in 
skeletal muscle, neuromuscular transmission was accelerated, 
and d-tubocurarine-induced muscle relaxation was antagonized 
[20]. Stimulation of α-2 adrenergic receptors in the central 
nervous system (CNS) depresses the release of catecholamine 
and acetylcholine and increases the effects of nondepolarizing 
muscle relaxants [21], consistent with the results of the present 
Table 2.  Onset and Recovery Times (min) in Rabbits given Rocuronium 0.6 mg/kg after Clonidine 4 μg/kg Daily Subcutaneous Injection for 3 or 
6 Weeks
Onset T1 (1) T1 (25) T1 (75) T1 (95) RI TOF (70)
Group C (n= 10)
Group S3 (n= 10)
Group S6 (n = 10)
0.4 ± 0.2
0.4 ± 0.1
0.3 ± 0.1
13.5 ± 1.7
14.2 ± 1.7
15.1 ± 1.9
16.4 ± 2.4
16.1 ± 2.2
15.6 ± 2.1
20.2 ± 2.9
20.4 ± 2.7
19.4 ± 2.6
22.6 ± 3.1
22.8 ± 2.9
21.3 ± 2.8
3.8 ± 0.7
4.3 ± 0.8
3.8 ± 0.7
24.1 ± 3.4
24.5 ± 3.1
23.9 ± 2.9
Data are expressed as mean ± SD. Onset: the time from injection of rocuronium to 100% twitch depression, T1 (1, 25, 75 and 95): the time from 
injection to recurrence, 25%, 75% and 95% recovery of first twitch of TOF (T1), respectively, RI: recovery index from to TOF 25% to 75% recovery 
of T1, TOF (70): the time from injection ratio (T4/T1) of 70%. Group C: control group, Group S3: after Clonidine 4 μg/kg daily sq for 3 weeks, 
Group S6: after Clonidine 4 μg/kg daily sq for 6 weeks. 194 www.ekja.org
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study but counter to the reports that the release of acetylcholine 
is not relevant to α-2 adrenergic receptors. Clonidine acts 
weakly on α-1 adrenergic receptors, but this interaction does 
not mediate the enhancement of muscle relaxation produced 
by rocuronium. Stimulation of α-1 adrenergic receptors boosts 
the release of acetylcholine [22] and may stop the reversal of 
rocuronium’s muscle relaxation effects. Leftward shifts of the 
dose-response curves in nondepolarizing muscle relaxants 
are elicited by dexmedetomidine (α-2 adrenergic receptor 
stimulant, an imidazole) or etomidate, which competitively or 
noncompetitively blocks nicotinic acetylcholine receptors [23] 
and clonidine also blocks nicotinic acetylcholine receptors [8]. 
    The ED50 and ED95 of rocuronium in rabbits were 61.5 ± 5.3 
μg/kg and 95.1 ± 6.7 μg/kg, respectively [24], and Kim et al. [25] 
argued that ED50 value of 56.5 μg/kg for rabbits corresponds 
to 40% of that reported for humans [26]. The present study 
also obtained similar results (64.1 ± 7.8 μg/kg). For humans, 
the onset time of neuromuscular blockade during anesthesia 
induced by nitrous oxide and narcotics was 1.5 min after an 
intravenous infusion of rocuronium (0.6 mg/kg) [27], whereas 
for rabbits, the onset time during thiopental sodium-induced 
anesthesia was 0.4 min after the same dose of rocuronium 
[25], as we also found, probably because rocuronium doses in 
rabbits (7 × ED95) are higher than in humans (2 × ED95). 
    Cardiac output and muscle blood flow determine the onset 
of a muscle relaxant, but we did not measure these variables. 
However, onset time and hemodynamic changes are probably 
minimal because the mean arterial pressure and pulse rates 
were similar in control and experimental groups. Muscle 
relaxants with low potency such as rocuronium need to be 
used in large doses to produce the same effect, which allows 
a large amount of rocuronium molecules to rapidly move to 
the neuromuscular junction and elicit faster onset times than 
past nondepolarizing muscle relaxants [28]. We could not 
discriminate differences between the two groups because of the 
rapid onset time of rocuronium. 
    Administration of clonidine for 3 or 6 weeks did not change 
the duration of action between the study and control groups. 
Pharmacodynamically, chronic nondepolarizing muscle 
relaxants may increase the number of nicotinic receptors [29]. 
Likewise, clonidine can increase neuromuscular receptors. 
Leftward shifts of the dose-response curves seems to indicate 
compensation by catecholamine receptors. Because the long-
term administration of clonidine did not affect mean arterial 
pressure and pulse rate, the clonidine dosage calculated for 
humans (4 μg/kg/day) may be too low to influence the rabbit’s 
cardiovascular system. Clonidine may not eliminate rocuronium 
or the sample size may be too small to see an effect. Therefore, 
further study is needed to measure the neuromuscular blocking 
action of clonidine in larger doses. We could not measure the 
blood concentration of rocuronium, so it is impossible to define 
plasma clearance and the volume of distribution. 
    Megadoses of α-2 adrenergic receptor stimulants (imidazole 
derivatives) such as clonidine or dexmedetomidine (i.e., 32 
and 320 μg/kg) produce muscle relaxation and analgesia [30]. 
We only used a small clinical dose (4 μg/kg/day) to prevent 
observations on analgesic effects.
    In conclusion, rocuronium in rabbits pretreated with 
clonidine for three or six weeks enhanced the effect of muscle 
relaxation or neuromuscular block, but made no difference on 
the duration of action between the experimental and control 
groups.
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